Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
156.1 USD | +0.37% | -3.98% | -13.45% |
06-20 | Beigene Insider Sold Shares Worth $368,162, According to a Recent SEC Filing | MT |
06-17 | BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Health Care Sector Index | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 4.58 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.45% | 16.45B | B | ||
+15.19% | 121B | B+ | ||
+19.91% | 114B | B+ | ||
-19.80% | 20.43B | B+ | ||
-15.92% | 16.55B | A- | ||
-44.35% | 15.59B | A- | ||
+66.67% | 15.19B | C+ | ||
+2.13% | 13.54B | C+ | ||
+119.39% | 10.96B | C | ||
+19.33% | 8.15B | - | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BGNE Stock
- Ratings BeiGene, Ltd.